Drug-resistant Streptococcus pneumoniae in community-acquired pneumonia

被引：4
作者：
Michael Henry
Howard L. Leaf
机构：
[1] Infectious Disease Section/III, VA New York Harbor Healthcare System, New York, NY 10010
来源：
Current Infectious Disease Reports | 2003年 / 5卷 / 3期
关键词：
Streptococcus Pneumoniae; Antimicrob Agent; Pneumococcal Pneumonia; Pneumococcal Infection; Macrolide Resistance;
D O I：
10.1007/s11908-003-0078-7
中图分类号：
学科分类号：
摘要：
The emergence of Streptococcus pneumoniae isolates resistant to not only penicillin, but to other antipneumococcal agents as well, has major public health implications. Drug-resistant S. pneumoniae are distributed worldwide, and resistance has become increasingly prevalent in the United States within the past decade. The relevance of resistance, particularly to the β-lactams, to treatment outcome has been subject to debate. Pneumonia due to intermediate-level-resistant penicillin-resistant isolates of S. pneumoniae appears to be adequately treated by β-lactam agents. Interpretation of resistance reports, which may be based on achievable cerebrospinal fluid levels of drug, may depend on the clinical setting, and efforts are underway to adjust breakpoints so that reports are more easily applicable to clinical practice. Infectious Diseases Society of America and American Thoracic Society guidelines, as well as others, for community-acquired pneumonia have addressed the impact of drug-resistant S. pneumoniae on antimicrobial selection. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：230 / 237
页数：7
相关论文
共 53 条
[21]  
Linares J., de la Campa A.G., Pallares R., Fluoroquinolone resistance in Streptococcus pneumoniae, N. Engl. J. Med., 341, pp. 1546-1547, (1999)
[22]  
Clavo-Sanchez A.J., Giron-Gonzalez J.A., Lopez-Prieto D., Et al., Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study, Clin. Infect. Dis., 24, pp. 1052-1059, (1997)
[23]  
Ewig S., Ruiz M., Torres A., Et al., Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae, Am. J. Respir. Crit. Care Med., 159, pp. 1835-1842, (1999)
[24]  
Deeks S.L., Palacio R., Ruvinsky R., Et al., Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pnuemoniae, Pediatrics, 103, pp. 409-413, (1999)
[25]  
Kellner J.D., McGeer A., Cetron M.S., Et al., The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease, Pediatr. Infect. Dis. J., 17, pp. 279-286, (1998)
[26]  
Kellner J.D., Ford-Jones E.L., Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers, Arch. Pediatr. Adolesc. Med., 153, pp. 495-502, (1999)
[27]  
Chiu S.S., Ho P.L., Chow F.K., Et al., Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong, Antimicrob. Agents Chemother., 45, pp. 2765-2770, (2001)
[28]  
Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement M100-S12
[29]  
Jorgensen J.H., Weigel L.M., Ferraro M.J., Et al., Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci, Antimicrob. Agents Chemother., 43, pp. 329-334, (1999)
[30]  
McCullers J.A., English B.K., Novak R., Isolation and characterization of vancomycin-toterant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis, J. Infect. Dis., 81, pp. 369-373, (2000)
123456